{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:23:38Z","timestamp":1778066618198,"version":"3.51.4"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013655","name":"Helmholtz-Fonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jconrel.2019.10.038","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T20:39:03Z","timestamp":1571776743000},"page":"62-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis"],"prefix":"10.1016","volume":"314","author":[{"given":"Nashrawan","family":"Lababidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Ofosu Kissi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8766-4568","authenticated-orcid":false,"given":"Walid A.M.","family":"Elgaher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Sigal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Haupenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca C.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.H.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7521-6020","authenticated-orcid":false,"given":"Thomas","family":"Rades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9260-7357","authenticated-orcid":false,"given":"Marc","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2019.10.038_bib0005","series-title":"The Metabolic and Molecular Basis of Inherited Disease","first-page":"5121","author":"Welsh","year":"2001"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0010","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.pupt.2007.12.001","article-title":"Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway","volume":"21","author":"Moreau-Marquis","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0015","series-title":"Cystic Fibrosis Foundation Patient Registry 2009 Annual Data Report","author":"B. Cystic Fibrosis Foundation, MD, USA","year":"2010"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0020","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","article-title":"Lung infections associated with cystic fibrosis","volume":"15","author":"Lyczak","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0025","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0030","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1183\/20734735.021014","article-title":"Inhaled therapy in cystic fibrosis: agents, devices and regimens","volume":"11","author":"Agent","year":"2015","journal-title":"Breathe"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0040","doi-asserted-by":"crossref","first-page":"e00019","DOI":"10.1128\/CMR.00019-18","article-title":"Epidemiology, biology, and impact of clonal Pseudomonas aeruginosa infections in cystic fibrosis","volume":"31","author":"Parkins","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0045","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1128\/AAC.01705-13","article-title":"Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration","volume":"58","author":"Yapa","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0050","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/03639045.2017.1318902","article-title":"Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients","volume":"43","author":"Akdag Cayli","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0055","article-title":"Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis","volume":"10","author":"Smith","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"14","key":"10.1016\/j.jconrel.2019.10.038_bib0060","doi-asserted-by":"crossref","DOI":"10.1093\/femsle\/fnx121","article-title":"Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"364","author":"Smith","year":"2017","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17560","article-title":"Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model","volume":"17","author":"Tappenden","year":"2013","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0070","first-page":"486","article-title":"TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"68","author":"Pierart","year":"2013","journal-title":"Rev. Med. Liege"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0075","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0080","article-title":"Inhaled anti\u2010pseudomonal antibiotics for long\u2010term therapy in cystic fibrosis","volume":"3","author":"Smith","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1208\/s12249-019-1314-2","article-title":"Delivery technologies for orally inhaled products: an update","volume":"20","author":"Moon","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0090","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1378\/chest.114.2.577","article-title":"Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation","volume":"114","author":"Standaert","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0095","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/bmj.295.6602.812","article-title":"Bacterial contamination of home nebuliser","volume":"295","author":"Barnes","year":"1987","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1067\/mic.2000.110214","article-title":"Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis","volume":"28","author":"Vassal","year":"2000","journal-title":"Am. J. Infect. Control"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0105","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1378\/chest.87.4.512","article-title":"Efficiency of air compressor-driven nebulizers","volume":"87","author":"Kradjan","year":"1985","journal-title":"Chest"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1378\/chest.123.1.28","article-title":"Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system","volume":"123","author":"Geller","year":"2003","journal-title":"Chest J."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/089426803764928347","article-title":"Lung deposition in cystic fibrosis patients using an ultrasonic or a jet nebulizer","volume":"16","author":"K\u00f6hler","year":"2003","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0120","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1023\/A:1016205520044","article-title":"Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers","volume":"12","author":"McCallion","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.addr.2014.04.004","article-title":"Technological and practical challenges of dry powder inhalers and formulations","volume":"75","author":"Hoppentocht","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0130","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejpb.2007.05.005","article-title":"Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients","volume":"68","author":"Pilcer","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0135","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2180-10-140","article-title":"N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa","volume":"10","author":"Zhao","year":"2010","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0140","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcf.2014.08.008","article-title":"Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial","volume":"14","author":"Conrad","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0145","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.rmed.2016.06.015","article-title":"The effect of N-acetylcysteine on biofilms: implications for the treatment of respiratory tract infections","volume":"117","author":"Blasi","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0150","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.gt.3301525","article-title":"Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium","volume":"8","author":"Ferrari","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0155","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1208\/s12249-008-9072-6","article-title":"Embryonic chicken trachea as a new in vitro model for the investigation of mucociliary particle clearance in the airways","volume":"9","author":"Henning","year":"2008","journal-title":"AAPS Pharm. Sci. Technol."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0160","series-title":"Remington: The Science and Practice of Pharmacy","first-page":"117","article-title":"Molecular structure, properties, and states of matter","author":"Rades","year":"2013"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0165","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1021\/acs.jpcb.7b10105","article-title":"Glass-transition temperature of the beta-relaxation as the major predictive parameter for recrystallization of neat amorphous drugs","volume":"122","author":"Kissi","year":"2018","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0170","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.ddtec.2011.10.002","article-title":"The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate","volume":"9","author":"Van den Mooter","year":"2012","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0175","series-title":"Amorphous Solid Dispersions: Theory and Practice","first-page":"35","article-title":"Theoretical considerations in developing amorphous solid dispersions","author":"Laitinen","year":"2014"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2015.12.009","article-title":"Recent advances in co-amorphous drug formulations","volume":"100","author":"Dengale","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0185","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ejpb.2013.03.014","article-title":"Amino acids as co-amorphous stabilizers for poorly water soluble drugs \u2013 part 1: preparation, stability and dissolution enhancement","volume":"85","author":"L\u00f6bmann","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0190","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1021\/acs.molpharmaceut.8b00650","article-title":"The role of glass transition temperatures in coamorphous drug-amino acid formulations","volume":"15","author":"Kissi","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0195","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijpharm.2017.09.063","article-title":"Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine","volume":"533","author":"Kasten","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0200","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0205","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2005.09.004","article-title":"The influence of formulation components on the aerosolisation properties of spray-dried powders","volume":"110","author":"Rabbani","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0210","article-title":"Influence of diluent and of copolymer composition on the glass temperature of a polymer system","volume":"I","author":"Fox","year":"1956","journal-title":"Bull. Am. Phys. Soc."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0215","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1002\/anie.201109258","article-title":"2\u2010Aminobenzimidazole derivatives strongly inhibit and disperse Pseudomonas aeruginosa biofilms","volume":"51","author":"Frei","year":"2012","journal-title":"Angew. Chemie Int. Ed."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0220","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1021\/acschembio.6b00117","article-title":"Application of dual inhibition concept within looped autoregulatory systems toward antivirulence agents against Pseudomonas aeruginosa infections","volume":"11","author":"Thomann","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0225","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1365-2958.2005.05008.x","article-title":"A characterization of DNA release in Pseudomonas aeruginosa cultures and biofilms","volume":"59","author":"Allesen\u2010Holm","year":"2006","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0230","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1039\/C3RA45820B","article-title":"Expanding the scaffold for bacterial RNA polymerase inhibitors: design, synthesis and structure\u2013activity relationships of ureido-heterocyclic-carboxylic acids","volume":"4","author":"Elgaher","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0235","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1128\/AAC.02600-14","article-title":"New insights into the bacterial RNA polymerase inhibitor CBR703 as a starting point for optimization as an anti-infective agent","volume":"58","author":"Zhu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijpharm.2012.04.067","article-title":"Conception, preparation and properties of functional carrier particles for pulmonary drug delivery","volume":"433","author":"Odziomek","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0245","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijpharm.2017.03.079","article-title":"Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: a focus on drug solubility","volume":"533","author":"Manniello","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0250","first-page":"21","volume":"24","author":"Stahl","year":"2002"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0255","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejpb.2016.02.010","article-title":"L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders","volume":"102","author":"Li","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0260","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejps.2016.08.022","article-title":"Development of a screening method for co-amorphous formulations of drugs and amino acids","volume":"95","author":"Kasten","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0265","series-title":"Analytical Techniques in the Pharmaceutical Sciences","article-title":"Thermal analysis of pharmaceuticals","author":"Qi","year":"2016"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0270","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jctb.5010020901","article-title":"Ideal copolymers and the second-order transitions of synthetic rubbers. I. Non-crystalline copolymers","volume":"2","author":"Gordon","year":"1952","journal-title":"J. Appl. Chem."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0275","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0280","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejps.2017.04.003","article-title":"The influence of mannitol on morphology and disintegration of spray-dried nano-embedded microparticles","volume":"104","author":"Torge","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0285","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.addr.2008.09.012","article-title":"Micro-and macrorheology of mucus","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0290","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrmicro2415","article-title":"The biofilm matrix","volume":"8","author":"Flemming","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0295","doi-asserted-by":"crossref","DOI":"10.1126\/science.295.5559.1487","article-title":"Extracellular DNA required for bacterial biofilm formation","volume":"295","author":"Whitchurch","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0300","doi-asserted-by":"crossref","first-page":"11541","DOI":"10.1073\/pnas.1218898110","article-title":"Self-organization of bacterial biofilms is facilitated by extracellular DNA","volume":"110","author":"Gloag","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000213","article-title":"Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms","volume":"4","author":"Mulcahy","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0310","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.addr.2007.05.010","article-title":"Salt formation to improve drug solubility","volume":"59","author":"Serajuddin","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0315","doi-asserted-by":"crossref","first-page":"737","DOI":"10.5301\/ijao.5000027","article-title":"Antibiotic-induced biofilm formation","volume":"34","author":"Kaplan","year":"2011","journal-title":"Int. J. Artif. Organs"},{"key":"10.1016\/j.jconrel.2019.10.038_bib0320","doi-asserted-by":"crossref","first-page":"19484","DOI":"10.1073\/pnas.0608949103","article-title":"Antibiotics as intermicrobial signaling agents instead of weapons","volume":"103","author":"Linares","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0325","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1128\/AAC.00017-15","article-title":"N-acetylcysteine selectively antagonizes the activity of imipenem in Pseudomonas aeruginosa by an OprD-mediated mechanism","volume":"59","author":"Rodr\u00edguez-Beltr\u00e1n","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2019.10.038_bib0330","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1128\/AAC.01334-16","article-title":"Effect of high N-acetylcysteine concentrations on antibiotic activity against a large collection of respiratory pathogens","volume":"60","author":"Landini","year":"2016","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919306029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919306029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:43:10Z","timestamp":1759160590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365919306029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":66,"alternative-id":["S0168365919306029"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.10.038","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.10.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}